PredniSONE Tablets, USP 10 mg

( DrugBank: Prednisone / KEGG DRUG: Prednisone )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
41	巨細胞性動脈炎	10

41. 巨細胞性動脈炎

臨床試験数 : 131 / 薬物数 : 139 - (DrugBank : 36) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 125

trials per page:

Showing 1 to 10 of 10 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-004809-31-SE (EUCTR)	11/01/2022	21/10/2021	Study of efficacy and safety of secukinumab 300 mgand 150 mgin patients with giant cell arteritis (G ...	A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to inves ...	giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ...	Trade Name: Cosentyx 300 mgsolution for injection in pre-filled syringe INN or Proposed INN: SECUKINU ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	348	Phase 3	United States;Portugal;Estonia;Spain;Russian Federation;Switzerland;Italy;France;Australia;Denmark;S ...
2	EUCTR2018-001003-36-HR (EUCTR)	10/04/2019	17/05/2019	A clinical study to test treatment of KPL-301 compared to placebo in giant cell arteritis	A Phase 2, randomized, double-blind placebo-controlled study to test the efficacy and safety of KPL- ...	giant cell arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell a ...	Product Name: Mavrilimumab Product Code: KPL-301 INN or Proposed INN: MAVRILIMUMAB Other descriptive na ...	Kiniksa Pharmaceuticals, Ltd. (Hamilton, Bermuda) c/o Kiniksa Pharmaceuticals Corp.	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2	United States;Serbia;Estonia;Slovenia;Spain;Ireland;United Kingdom;Italy;Belgium;Poland;Croatia;Aust ...
3	EUCTR2018-001003-36-DE (EUCTR)	27/02/2019	21/06/2018	A clinical study to test treatment of KPL-301 compared to placebo in giant cell arteritis	A Phase 2, randomized, double-blind placebo-controlled study to test the efficacy and safety of KPL- ...	giant cell arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell a ...	Product Name: Mavrilimumab Product Code: KPL-301 INN or Proposed INN: MAVRILIMUMAB Other descriptive na ...	Kiniksa Pharmaceuticals, Ltd. (Hamilton, Bermuda) c/o Kiniksa Pharmaceuticals Corp.	NULL	Not Recruiting			Female: yes Male: yes	70	Phase 2	United States;Serbia;Estonia;Slovenia;Spain;Ireland;United Kingdom;Italy;Belgium;Poland;Croatia;Aust ...
4	EUCTR2018-001003-36-GB (EUCTR)	06/12/2018	20/06/2018	A clinical study to test treatment of KPL-301 compared to placebo in giant cell arteritis	A Phase 2, randomized, double-blind placebo-controlled study to test the efficacy and safety of KPL- ...	giant cell arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell a ...	Product Name: Mavrilimumab Product Code: KPL-301 INN or Proposed INN: MAVRILIMUMAB Other descriptive na ...	Kiniksa Pharmaceuticals, Ltd. (Hamilton, Bermuda) c/o Kiniksa Pharmaceuticals Corp.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	70	Phase 2	United States;Serbia;Estonia;Slovenia;Spain;Ireland;United Kingdom;Italy;Belgium;Poland;Croatia;Aust ...
5	EUCTR2018-001003-36-IT (EUCTR)	30/11/2018	11/10/2018	A clinical study to test treatment of KPL-301 compared to placebo in giant cell arteritis	A Phase 2, randomized, double-blind placebo-controlled study to test the efficacy and safety of KPL- ...	giant cell arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell a ...	Product Name: Mavrilimumab Product Code: KPL-301 INN or Proposed INN: MAVRILIMUMAB Other descriptive na ...	Kiniksa Pharmaceuticals, Ltd. (Hamilton, Bermuda) c/o Kiniksa Pharmaceuticals Corp.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 2	Serbia;United States;Estonia;Slovenia;Spain;Ireland;Italy;United Kingdom;Poland;Belgium;Croatia;Aust ...
6	EUCTR2018-001003-36-BE (EUCTR)	28/11/2018	16/08/2018	A clinical study to test treatment of KPL-301 compared to placebo in giant cell arteritis	A Phase 2, randomized, double-blind placebo-controlled study to test the efficacy and safety of KPL- ...	giant cell arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell a ...	Product Name: Mavrilimumab Product Code: KPL-301 INN or Proposed INN: MAVRILIMUMAB Other descriptive na ...	Kiniksa Pharmaceuticals, Ltd. (Hamilton, Bermuda) c/o Kiniksa Pharmaceuticals Corp.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 2	Serbia;United States;Estonia;Slovenia;Spain;Ireland;United Kingdom;Italy;Poland;Belgium;Croatia;Aust ...
7	EUCTR2018-001003-36-NL (EUCTR)	13/11/2018	29/06/2018	A clinical study to test treatment of KPL-301 compared to placebo in giant cell arteritis	A Phase 2, randomized, double-blind placebo-controlled study to test the efficacy and safety of KPL- ...	giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ...	Product Name: Mavrilimumab Product Code: KPL-301 INN or Proposed INN: MAVRILIMUMAB Other descriptive na ...	Kiniksa Pharmaceuticals, Ltd. (Hamilton, Bermuda) c/o Kiniksa Pharmaceuticals Corp.	NULL	Not Recruiting			Female: yes Male: yes	70	Phase 2	Serbia;United States;Estonia;Slovenia;Spain;Ireland;United Kingdom;Italy;Belgium;Poland;Croatia;Aust ...
8	EUCTR2018-001003-36-SI (EUCTR)	03/10/2018	30/08/2018	A clinical study to test treatment of KPL-301 compared to placebo in giant cell arteritis	A Phase 2, randomized, double-blind placebo-controlled study to test the efficacy and safety of KPL- ...	giant cell arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell a ...	Product Name: Mavrilimumab Product Code: KPL-301 INN or Proposed INN: MAVRILIMUMAB Other descriptive na ...	Kiniksa Pharmaceuticals, Ltd. (Hamilton, Bermuda) c/o Kiniksa Pharmaceuticals Corp.	NULL	Not Recruiting			Female: yes Male: yes	70	Phase 2	United States;Serbia;Estonia;Slovenia;Spain;Ireland;United Kingdom;Italy;Belgium;Poland;Croatia;Aust ...
9	EUCTR2018-001003-36-ES (EUCTR)	08/08/2018	28/06/2018	A clinical study to test treatment of KPL-301 compared to placebo in giant cell arteritis	A Phase 2, randomized, double-blind placebo-controlled study to test the efficacy and safety of KPL- ...	giant cell arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell a ...	Product Name: Mavrilimumab Product Code: KPL-301 INN or Proposed INN: MAVRILIMUMAB Other descriptive na ...	Kiniksa Pharmaceuticals, Ltd. (Hamilton, Bermuda) c/o Kiniksa Pharmaceuticals Corp.	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2	United States;Serbia;Estonia;Slovenia;Spain;Ireland;United Kingdom;Italy;Belgium;Poland;Croatia;Aust ...
10	EUCTR2018-001003-36-EE (EUCTR)	09/07/2018	11/06/2018	A clinical study to test treatment of KPL-301 compared to placebo in giant cell arteritis	A Phase 2, randomized, double-blind placebo-controlled study to test the efficacy and safety of KPL- ...	giant cell arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell a ...	Product Name: Mavrilimumab Product Code: KPL-301 INN or Proposed INN: MAVRILIMUMAB Other descriptive na ...	Kiniksa Pharmaceuticals, Ltd. (Hamilton, Bermuda) c/o Kiniksa Pharmaceuticals Corp.	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2	United States;Serbia;Estonia;Slovenia;Spain;Ireland;United Kingdom;Italy;Belgium;Poland;Croatia;Aust ...

First Previous1Next Last